AI in Pharmaceutical & MedTech Supply Chains

The escalating complexity of global pharmaceutical and medical technology supply chains, regulatory demands, and increasing personalisation of care have intensified interest in Artificial Intelligence (AI) to enhance resilience, responsiveness, and traceability.
According to a 2025 industry survey, the adoption of AI in pharma supply chains has shifted from pilot projects to practical deployment, with investment expanding beyond basic monitoring to predictive planning and risk mitigation.
AI promises automated decision support and optimisation of logistics processes. However, maturity and applicability vary across functions and contexts.

Pharma.Aero initiated this project to assess how AI can augment human decision-making processes within a pharmaceutical/MedTech supply chain context. Rather than treating AI as a fully autonomous solution, the project explores human-centred design principles, task reconfiguration that relieve pain points or create gains in regulated supply chain environments. Particular attention is given to decision ownership, workforce implications, and regulatory alignment, including compliance with GMP and GDP requirements and MoH expectations and interpretations regarding human ownership versus automation.

The outcome of this project will be an actionable framework to support responsible and effective AI integration in pharmaceutical and MedTech supply chains. This framework will address technological readiness alongside ethical considerations, regulatory expectations, and workforce impacts, enabling industry partners to make informed decisions about AI adoption, investment priorities, and future pilot initiatives.